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against the existing therapy buproprion SR. METHODS: A deci-
sion analytic model was developed using DATA Treeage software
to compare the cost-effectiveness of varenicline with buproprion
SR. The costs and probabilities of success were reported for 12
weeks for 1 mg varenicline and 150 mg buproprion SR. The drug
acquisition costs were obtained from the Drug Topics Red Book
and published clinical trials. The model also included costs and
effectiveness values for placebo. Costs for physician visits and
counseling were obtained from clinical trials and other published
sources. The probabilities of success were reported as the con-
tinuous abstinence rate (CAR) in all the studies. Treatment effects
were compared using head-to-head clinical trials. Incremental
cost effectiveness ratios (ICERs) were calculated for additional
cost/CAR and were estimated relative to placebo. One- way
sensitivity analysis was performed to determine the robustness of
the results. RESULTS: The ICER for varenicline compared to
placebo was $3688/CAR, and the ICER for buproprion SR com-
pared to placebo was $5915/CAR. The total costs of varenicline
and buproprion SR were $1696.2 and $1833.6 respectively.
Varenicline was found to be more effective than buproprion SR
and placebo with a CAR of 0.46, compared to CARs of 0.31 and
0.17 respectively. Sensitivity analysis indicated that the results
were affected by the model assumptions for cost and effectiveness
treatment options. CONCLUSION: Based on the results from
the decision analytic model, smoking cessation therapy with
varenicline should result in lower costs, and higher CARs as
compared to buproprion SR.
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OBJECTIVE: The objective of this study was to assess the cost-
effectiveness of ciclesonide versus ﬂuticasone in adult patients
with mild, moderate, and severe asthma. METHODS: A decision
tree model was developed to simulate the health consequences
and costs associated with daily asthma medication use. Patients
were assumed to receive either ciclesonide or ﬂuticasone. Poten-
tial health consequences for patients in the model included an
adverse drug event (ADE) and symptom-free (SF) day. Costs
included those associated with drug acquisition, the use of rescue
medication, and medical resource utilization due to ADEs or
non-SF days. The efﬁcacy of ciclesonide and ﬂuticasone was
estimated using data from multiple clinical trials and data on ﬁle
at Sanoﬁ-Aventis. Data on medical resource utilization following
ADEs and costs were estimated from published literature. Parity
in the cost of ciclesonide and ﬂuticasone was assumed. The
model was used to calculate total daily costs, probability of an
ADE-free (ADEF)/SF day, and the incremental cost per ADEF/SF
day for ciclesonide versus ﬂuticasone. RESULTS: The use of
ciclesonide is associated with lower costs ($2.01 vs. $2.02) and
higher probability of an ADEF/SF day (0.254 vs. 0.247) than
ﬂuticasone, indicating that ciclesonide dominates ﬂuticasone in
the treatment of patients with varying asthma severity. Results of
a one-way sensitivity analysis of all model parameters suggest
that the model is most sensitive to changes in the probability of
a symptom-free day on treatment with ﬂuticasone. A two-fold
increase in the cost of ciclesonide yields an ICER of $88.38 per
ADEF/SF day. CONCLUSION: Ciclesonide produces more
ADEF/SF days than ﬂuticasone and therefore dominates ﬂutica-
sone when drug prices are equal.
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OBJECTIVE: We undertook a systematic review of asthma inter-
vention health economic studies from 2002 through 2007, evalu-
ated how well the current health economic recommendations in
asthma have been followed, assessed the implications of health
economics research by comparing ﬁndings to coverage and reim-
bursement patterns and, suggested avenues for future improve-
ment. METHODS: We performed a state-of-the-art review using
multiple search databases. We used past health economic asthma
reviews to assess whether current studies have complied with
previous recommendations. We compared the pharmaceutical
value-for-money conclusions with their formulary coverage from
a large payer in the US and the British reimbursement recom-
mendations. RESULTS: We included 39 of the 176 studies that
met our initial criteria. Data sources used to inform the economic
analyses ranged in duration from 12 weeks (8) to three years (2).
Uncertainty was reported by 19 studies. The most common
beneﬁt outcome was symptom free days (14). Seven studies
reported quality-adjusted life years. Thirty-four of 39 reported
that the intervention of interest was cost-effective or dominant.
CONCLUSION: Previous recommendations for longer-term
pragmatic trials are still germane. Using the Global Initiative for
Asthma guidelines, the reviewed pharmaceutical interventions
assumed relevant comparators but few studies compared combi-
nation products to their collective components. Care should be
taken in the interpretation of incremental cost-effectiveness ratios
that use asthma speciﬁc event avoided outcomes because these
outcomes may not capture the complete effects of treatment and
may be biased due to double counting. We recommend the use of
generic measures sensitive to asthma patients and standardized
across diseases. Willingness-to-pay must be assumed to conclude
cost-effectiveness and must be justiﬁed. The overall ﬁndings from
this health technology assessment review are consistent with
the coverage and reimbursement recommendations in the UK
(British Thoracic Society and Scottish Intercollegiate Guidelines
Network) and US (Aetna’s 2007 preferred drug guide).
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OBJECTIVE: To assess the cost-effectiveness of empirical outpa-
tient treatment options in Canada for community-acquired
pneumonia (CAP) in the presence of antimicrobial resistance.
METHODS: A multi-country decision analytic model to assess
the clinical and economic consequences of antimicrobial resis-
tance, developed for mild-to-moderate empirical CAP outpa-
tient treatment, was adapted to Canada. Treatment algorithms
involved ﬁrst- and second-line treatment in the community, and
incorporated follow-up after treatment failure due to resistance
or other reasons and resulting hospitalizations. Comparators
included (1) ﬁrst-line treatment with azithromycin, a generic
macrolide prescribed in Canada, followed by moxiﬂoxacin, a
ﬂuoroquinolone, and (2) ﬁrst-line treatment with moxiﬂoxacin
followed by azithromycin upon failure. Clinical failure rates with
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antimicrobial-susceptible and -resistant pathogens were obtained
from the literature or estimated. Resistance and co-resistance
prevalence to ﬁrst- and second-line therapy for the major CAP
pathogens were also derived from local surveillance studies.
Resource use was obtained from Canadian published sources.
Total costs were estimated using standard Ontario sources and a
third-party payer perspective. Outcome measures included ﬁrst-
line clinical failure, second-line treatment and hospitalizations
avoided. RESULTS: The base case incremental cost-effectiveness
ratios (ICERs) comparing moxiﬂoxacin/azithromycin with
azithromycin/moxiﬂoxacin were CDN$96.04 per clinical failure
avoided, CDN$118.71 per second-line treatment avoided, and
CDN$502.47 per hospitalization avoided. One-way sensitivity
analyses demonstrated that the model is robust to change.
The probabilistic sensitivity analysis reported a mean ICER of
CDN$133 (Sd601.47) per clinical failure avoided and a 22%
probability of a moxiﬂoxacin/azithromycin strategy being
cost-saving compared to azithromycin/moxiﬂoxacin. CONCLU-
SION: Antimicrobial failure signiﬁcantly affected outcomes and
costs in empirical outpatient CAP treatment. Despite the higher
costs of proprietary antimicrobial treatments in Canada com-
pared to generic treatments, ﬁrst-line treatment with a ﬂuoroqui-
nolone effective against the major CAP pathogens, including
strains resistant to other antimicrobials, produces signiﬁcantly
better clinical outcomes and relatively low total treatment costs
compared to generic drugs.
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OBJECTIVE: The objectives of this analysis were to: 1)Identify a
population of asthma patients new to treatment with omali-
zumab; 2)measure asthma-speciﬁc treatment costs and utilization
for patients initiating treatment with omalizumab; and compare
and quantify, on an annual basis, differences in economics and
other measurable outcomes following initiation of treatment
with omalizumab. METHODS: Using integrated medical and
pharmacy claims data (obtained from the IMS/Pharmetrics
Patient-centric Database), patients were included in the analysis
based on the presence of a diagnosis of asthma (ICD-9 code
493.*) during calendar years 2004 through 2005. Additional
requirements included incident (new) use of omalizumab in
2004. Clinical and economic information related to the treat-
ment of asthma were captured using Episode Treatment Group
(ETG) episode-building software. RESULTS: In 2004, 542
patients (representing 0.1% of the overall asthma population)
were identiﬁed as being newly treated with omalizumab. Within
this group, 66% were diagnosed with extrinsic asthma and 78%
with rhinitis. Total annual costs related to the care of asthma for
this group was $16,643 with $5,926 in medical expenditures.
Following these patients into the next calendar year (2005),
pharmacy costs increased by 33% but medical costs decreased by
42% (to $3411), driven primarily by lower inpatient utilization,
admission rates (from 6.1% to 3.8%), and emergency room
utilization. Additionally, there was decreased use of oral corti-
costeroids and overall use of asthma controllers. CONCLU-
SION: Treatment with omalizumab represents a signiﬁcant
pharmacy investment, and measurable beneﬁts were observed
with respect to medical expenditures and asthma-speciﬁc out-
comes. However, these observations are limited to a very speciﬁc
patient population and further study may be necessary to deter-
mine applicability to other patient groups.
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OBJECTIVE: To compare cost-effectiveness (CE) and cost-utility
(CU) for varenicline vs. other interventions used for smoking
cessation in Czech Republic. METHODS: The Beneﬁt of
Smoking Cessation on Outcomes (BENESCO) Markov simula-
tion model was employed to compare different approaches. The
model simulates morbidity and mortality for the Czech popula-
tion of smokers. In our model a 20-years time horizon was used
to calculate costs and beneﬁts from the payer’s perspective under
current conditions (smoking cessation interventions are not reim-
bursed). Five co-morbidities were considered: chronic obstructive
pulmonary disease, coronary heart disease, stroke, lung cancer
and asthma exacerbations. Calculations were performed in 2007
costs and prices, assuming that 25% of smokers in each age
group make one attempt to quit smoking. Abstinence rates were
extrapolated from literature sources. Local costs and data were
obtained either from literature or expert panels. Assessed inter-
ventions included varenicline, bupropion, nicotine replacement
therapy (NRT) and unaided cessation. RESULTS: Varenicline
dominated all other interventions both in QALY and LYG, and
was cost-saving over the assessed period of 20 years. Beneﬁt of
varenicline was most signiﬁcant in comparison with unaided
cessation (QALY gained 18,186, LYG 12,243, deaths avoided
2004, costs saved €35.5 million—data for all smokers exposed to
intervention). Varenicline was also dominant in comparison to
the most frequently used approach—NRT (QALY gained 7358,
LYG 4953, deaths avoided 811, costs saved €13 million). Bupro-
pion showed similar results to NRT. Varenicline dominated all
other interventions already after ﬁve years. CONCLUSION:
Varenicline is the most effective and cost-effective smoking ces-
sation intervention in Czech Republic from the health care
payer’s perspective. As the prevalence of smokers is high; health
care providers should consider smoking cessation support,
including reimbursement strategies. Further scenarios to conﬁrm
CE and CU also under these conditions are needed.
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OBJECTIVE: To assess the incremental cost-effectiveness of
combining tiotropium (TIO) with salmeterol (SAL) or
salmeterol-ﬂuticasone (SFC) in moderate to severe COPD com-
pared with TIO alone. METHODS: A Markov model was con-
structed to estimate the incremental quality-adjusted life-years
(QALYs) of the three treatment arms. Efﬁcacy data were
obtained from a recently published large randomized controlled
study (Canadian Optimal Therapy of COPD trial). Cost data
were obtained from publicly available data. The cycle length for
the model was set to 3 months and the maximum time horizon
was set to 3 years. The cost-effective analysis was conducted
from a third-party payer’s perspective in the US health care
system. Future costs and effects were discounted at 3%. All costs
are reported in 2007 dollars. Multiple one-way sensitivity analy-
ses and a Monte Carlo simulation were performed to handle
uncertainty. RESULTS: Incremental cost-effectiveness ratios
compared with TIO alone were $152,743/QALY in the
TIO + SAL group, and $51,610/QALY in the TIO + SFC group.
An acceptability curve revealed TIO + SAL was more cost-
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